IMUX Rasio cepet Immunic Therapeutics

This price chart serves as an indicator for Immunic, Inc. (IMUX), which develops convenient tablet-based treatments for multiple sclerosis. Immunic, Inc. (IMUX) aims to outperform market leaders in the scientific race, establishing a long-term profit generator through multi-year patient therapy. The current ratio is 5.21. Meanwhile, the business is implementing zero-waste substance synthesis and strictly controlling chemical disposal as part of its environmental policy.

The quick ratio measures a company's ability to instantaneously settle short-term liabilities using only cash and accounts receivable, excluding slow-moving inventories. By analyzing the quick ratio time series, an investor assesses the financial resilience of Immunic, Inc. (IMUX) to market shocks, which is critical for ensuring the development of innovative molecules and protecting pricing power in multiple sclerosis therapy.